U.S. flag

An official website of the United States government

GTR Home > Tests > Genetic study of pharmacogenetics


This is a clinical test intended for Help: Drug Response, Therapeutic management

Clinical summary


Check Clinical features section (below), Conditions for which test is offered (above), and links on the right for additional information about this condition.

Conditions tested

Target population


MyPharmaGenes tests 88 genetic variants on ABCB1, ABCG2, APOE, C11orf65, COMT, CYP1A2, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, DPYD, DRD2, F2, F5, GSTP1, HLA-A, HLA-B, HTR2A, HTR2C, MC4R, MTHFR, NUDT15, OPRM1, SLCO1B1, TCF7L2, TPMT, UGT1A1, VKORC1 genes to study its pharmacogenetics traits. Clinical context for which is prescribed: Diabetes, Oncology, Psychiatry, Neurology, Pain management and Cardiovascular diseases. > Patients who are starting new therapies; > Patients who are not achieving therapeutic goals and/or experience moderate to severe adverse effects with the current therapy; > Any person that would like to be informed about their genetic predisposition to respond to certain drugs.


  • Pharmacogenetics

Clinical validity


Not provided

Clinical utility


Guidance for selecting a drug therapy and/or dose


IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.